#USA #Cambrex #API Manufacturing #Drug Supply #Charles City

Cambrex's Bold Move to Strengthen U.S. Drug Manufacturing

Cambrex, a key player in the global contract development and manufacturing organization (CDMO) sector, has announced a groundbreaking investment of $120 million aimed at expanding its active pharmaceutical ingredient (API) manufacturing capabilities in the United States. This strategic move aligns with the rising demand for drug production in the U.S., which has emerged as the world’s largest pharmaceutical market.

Overview of the Investment

The announced investment will facilitate a 40% increase in production capacity at Cambrex's Iowa facility in Charles City, enhancing output to nearly one million liters. This facility is renowned for producing a wide array of APIs and pharmaceutical intermediates, specializing in highly potent molecules and controlled substances. CEO Thomas Loewald emphasized the critical role of local API production in ensuring the safety and resilience of the drug supply chain. He stated, “Our customers, in partnership with federal and state agencies, are relocating drug manufacturing to the U.S. Cambrex will play a pivotal role in this transition.”

Responding to Market Demands

As the pharmaceutical landscape evolves, clients express significant interest in collaborating with Cambrex to leverage this increased capacity. Loewald added, “We are witnessing strong demand from clients wishing to partner with us to capitalize on this enhanced capability.” The investment is not only a response to current market needs but also a proactive measure to ensure a stable long-term supply of critical therapies domestically.

Commitment to U.S. Manufacturing

Following a trend of investment, Cambrex is keen on fortifying the stability of pharmaceutical manufacturing in the U.S. Over the last five years, the company has consistently enhanced its capabilities, highlighted by:

• - 2022: Addition of high potency APIs and large-scale manufacturing capacity in Iowa.
• - 2023: Establishing modern laboratories and manufacturing capabilities focused on rare disease therapies in High Point, North Carolina.
• - 2025: Expanding GMP production for peptide therapeutics in Waltham, Massachusetts.

These incremental investments underscore Cambrex's commitment to evolving its expertise and meeting the growing demands of the pharmaceutical industry.

About Cambrex

Cambrex’s proficient team of 2,000 experts has been at the forefront of drug development for over 40 years. They offer extensive technological capabilities in various areas, including continuous flow chemistry, controlled substances, peptide synthesis, solid-state science, material characterization, and high potency APIs. This robust history positions Cambrex as a leading entity in providing comprehensive analytical services and support for drug development throughout the lifecycle of medications.

As Cambrex moves forward with this $120 million investment, it signifies not only a boost in production capabilities but also a strengthening of the pharmaceutical supply chain in the U.S., ensuring that critical therapies remain accessible and resilient amidst global uncertainties. The investment reflects the company’s steadfast dedication to its clients and the ongoing evolution of the pharmaceutical landscape.